BC

Biofil Chemicals & Pharmaceuticals Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Biofil Chemicals & Pharmaceuticals Q2 Results 2026: PAT ₹0 Cr +50%

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹2Cr
−87.7% YoY
−86.5% QoQ
Net profit
₹0Cr
+50% YoY
+9.1% QoQ
Margin
6%
+5.2 pp YoY
+4.9 pp QoQ

Biofil Chemicals & Pharmaceuticals Ltd Q2 FY27 key numbers

Revenue
Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs.

As stated in Biofil Chemicals & Pharmaceuticals Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.

Based on Biofil Chemicals & Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹31
Market cap₹52 Cr
P/E107.7

The short version

Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Quarterly EBITDA: Rs. 56 Crores, up 54% YoY.

From Biofil Chemicals & Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Biofil Chemicals & Pharmaceuticals' revenue grow in the September 2026 quarter?

  • Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs.
  • Corresponding Quarter Previous Year (Q2 30/09/2025): ₹1,214.47 Lakhs (Pharma Unit), ₹139.61 Lakhs (Chemicals Division); Total Gross Turnover ₹1,354.08 Lakhs.
  • Year-on-Year Revenue Change for Pharma Unit: Decrease from ₹1,214.47 Lakhs (prev. year quarter) to ₹166.87 Lakhs (current quarter).

2 more points from Biofil Chemicals & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

What happened to Biofil Chemicals & Pharmaceuticals' margins in Q2 FY27?

Quarterly EBITDA: Rs. 56 Crores, up 54% YoY.

Locked: what Biofil Chemicals & Pharmaceuticals Ltd said on margins

Also locked on this page: fundraising

Free account, 30 seconds. No card needed.

What capex is Biofil Chemicals & Pharmaceuticals planning?

  • The company is undertaking renovation and upgradation of its manufacturing facility pursuant to the revision in Schedule M of the Drugs and Cosmetics Rules.
  • The upgradation work is expected to be completed within approximately 3 to 6 months from the date of the report (November 14, 2026).
  • The enhanced manufacturing capabilities, upon completion, are expected to improve sales in subsequent periods.
  • Capital expenditure in property, plant, and equipment during the half year ended 30.09.2026 was ₹9.20 Lakhs.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Biofil Chemicals & Pharmaceuticals raising money or cutting debt?

The cash flow statement on page 8 shows cash flow from financing activities with a net decrease in…

Locked: what Biofil Chemicals & Pharmaceuticals Ltd said on fundraising

Also locked on this page: margins

Free account, 30 seconds. No card needed.

How big is Biofil Chemicals & Pharmaceuticals' order book?

  • Financial data provided focus on segment revenue, profit, capital employed, assets, liabilities, cash flow, and earnings.
  • No operational metrics related to order bookings or order inflows are included.

Biofil Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Biofil Chemicals & Pharmaceuticals Ltd Q2 FY27 results — key figures

Biofil Chemicals & Pharmaceuticals Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue214-87.7%12-86.5%
Operating profit (EBITDA)00-9.1%0-28.6%
Operating margin6%0.8%+5.2 pp1.1%+4.9 pp
Profit before tax00+36.4%0+15.4%
Net profit (PAT)00+50%0+9.1%
EPS (₹)0.070.05+40%0.070%

Source: Biofil Chemicals & Pharmaceuticals Ltd's results filing to NSE (standalone), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Alpa Laboratorie (Q2 FY27)

    Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aarey Drugs (Q2 FY27)

    Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biofil Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biofil Chemicals & Pharmaceuticals Ltd Q2 FY27 results?

Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Quarterly EBITDA: Rs. 56 Crores, up 54% YoY.

What is Biofil Chemicals & Pharmaceuticals Ltd share price analysis?

Biofil Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 107.7 with a market cap of ₹52 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biofil Chemicals & Pharmaceuticals Ltd planning capital expenditure?

The company is undertaking renovation and upgradation of its manufacturing facility pursuant to the revision in Schedule M of the Drugs and Cosmetics Rules.

Keep Biofil Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.